IFN-γ Induces PD-L1 Expression in Primed Human Basophils

被引:13
作者
Bonam, Srinivasa Reddy [1 ]
Chauvin, Camille [1 ]
Mathew, Mano J. [2 ]
Bayry, Jagadeesh [1 ,3 ]
机构
[1] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, Inst Natl Sante & Rech Med, F-75006 Paris, France
[2] EFREI, F-94800 Villejuif, France
[3] Indian Inst Technol Palakkad, Dept Biol Sci & Engn, Palakkad 678623, India
关键词
human basophils; PD-L1; IFN-gamma; IL-3; IL-4; IL-13; IFNGR2; UP-REGULATION; OX40; LIGAND; INTERFERON-GAMMA; TH2; RESPONSES; B7-H1; ROLES; CELLS; ACTIVATION; MECHANISMS; COVID-19;
D O I
10.3390/cells11050801
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Programmed death-ligand 1 (PD-L1) plays a key role in maintaining immune tolerance and also in immune evasion of cancers and pathogens. Though the identity of stimuli that induce PD-L1 in various human innate cells and their function are relatively well studied, data on the basophils remain scarce. In this study, we have identified one of the factors, such as IFN-gamma, that induces PD-L1 expression in human basophils. Interestingly, we found that basophil priming by IL-3 is indispensable for IFN-gamma -induced PD-L1 expression in human basophils. However, priming by other cytokines including granulocyte-macrophage colony-stimulating factor (GM-CSF) and thymic stromal lymphopoietin (TSLP) was dispensable. Analyses of a published microarray data set on IL-3-treated basophils indicated that IL-3 enhances IFNGR2, one of the chains of the IFNGR heterodimer complex, and CD274, thus providing a mechanistic insight into the role of IL-3 priming in IFN-gamma -induced PD-L1 expression in human basophils.
引用
收藏
页数:15
相关论文
共 53 条
[1]   Off balance: Interferons in COVID-19 lung infections [J].
Akamatsu, Milena ;
de Castro, Tavares ;
Takano, Carolina Yumi ;
Ho, Paulo Lee .
EBIOMEDICINE, 2021, 73
[2]   Basophil activation through TLR2 and TLR4 signaling pathways [J].
Alkan, Manal ;
Sayes, Fadel ;
Ramadan, Abdulraouf ;
Machavoine, Francois ;
Dy, Michel ;
Schneider, Elke ;
Thieblemont, Nathalie .
AIMS ALLERGY AND IMMUNOLOGY, 2018, 2 (03) :126-140
[3]  
Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO
[4]  
2-4
[5]   Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections [J].
Benard, Alan ;
Jacobsen, Anne ;
Brunner, Maximilian ;
Krautz, Christian ;
Kloesch, Bettina ;
Swierzy, Izabela ;
Naschberger, Elisabeth ;
Podolska, Malgorzata J. ;
Kouhestani, Dina ;
David, Paul ;
Birkholz, Torsten ;
Castellanos, Ixchel ;
Trufa, Denis ;
Sirbu, Horia ;
Vetter, Marcel ;
Kremer, Andreas E. ;
Hildner, Kai ;
Hecker, Andreas ;
Edinger, Fabian ;
Tenbusch, Matthias ;
Muehl-Zuerbes, Petra ;
Steinkasserer, Alexander ;
Richter, Enrico ;
Streeck, Hendrik ;
Berger, Marc M. ;
Brenner, Thorsten ;
Weigand, Markus A. ;
Swirski, Filip K. ;
Schett, Georg ;
Gruetzmann, Robert ;
Weber, Georg F. .
NATURE COMMUNICATIONS, 2021, 12 (01)
[6]   Toll-like receptor 2 ligands activate human basophils for both IgE-dependent and IgE-independent secretion [J].
Bieneman, AP ;
Chichester, KL ;
Chen, YH ;
Schroeder, JT .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 115 (02) :295-301
[7]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[8]   SARS-CoV-2 Induces Cytokine Responses in Human Basophils [J].
Bonam, Srinivasa Reddy ;
Chauvin, Camille ;
Levillayer, Laurine ;
Mathew, Mano Joseph ;
Sakuntabhai, Anavaj ;
Bayry, Jagadeesh .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[9]   Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: A possible role in asthma? [J].
Burgess, JK ;
Carlin, S ;
Pack, RA ;
Arndt, GM ;
Au, WW ;
Johnson, PRA ;
Black, JL ;
Hunt, NH .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (04) :683-689
[10]   Mechanisms regulating PD-L1 expression on tumor and immune cells [J].
Chen, Shuming ;
Crabill, George A. ;
Pritchard, Theresa S. ;
McMiller, Tracee L. ;
Wei, Ping ;
Pardoll, Drew M. ;
Pan, Fan ;
Topalian, Suzanne L. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)